Auna S.A.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AUNA research report →
Range $6.9 – $9
Price Chart
About the company
Auna S. A. operates as a healthcare services provider, overseeing a network of hospitals and clinics across Mexico, Peru, and Colombia.
- CEO
- Jesús Antonio Zamora Leon
- IPO
- 2024
- Employees
- 15,254
- HQ
- Luxembourg, LU, LU
Get TickerSpark's AI analysis on AUNA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $271.05M
- P/E
- -89.39
- Fwd P/E
- 1.38
- PEG
- 0.84
- P/S
- 0.21
- P/B
- 0.52
- EV/EBITDA
- 1.69
- Div Yield
- 0.00%
- Gross Margin
- 35.90%
- Op Margin
- 12.27%
- Net Margin
- -0.26%
- ROE
- -0.72%
- ROIC
- 0.50%
Latest fiscal year · YoY change
- Revenue
- $4.39B-0.0%
- Gross Profit
- $1.66B-3.6%
- Op Income
- $631.27M
- Net Income
- $97.61M-11.5%
- EPS
- $1.32-19.5%
- OCF Growth
- -63.7%
- FCF Growth
- -72.0%
- 52W High
- $6.29
- 52W Low
- $3.63
- 50D MA
- $4.95
- 200D MA
- $5.09
- Beta
- 0.66
- RSI (14)
- 24
- Avg Volume
- 159.21K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Auna posted solid third-quarter revenue growth and strong cash generation, but profitability was pressured by a terminated Colombia oncology contract and Peru billing penalties.· November 18, 2026
- FX-neutral revenue grew 10% year over year, with Mexico accelerating and Peru and Colombia still showing underlying demand momentum.
- Mexico delivered its first year-over-year adjusted EBITDA growth of 2026, helped by higher surgeries and oncology volumes.
- Colombia revenue rose 12% in local currency, but adjusted EBITDA fell 30% because of a specific oncology risk-sharing contract and price caps.
- Peru revenue improved on higher surgery and oncology volumes, but EBITDA was hit by billing-related penalties and higher operating costs.
- Free cash flow rose 95% year to date, leverage improved to 3.5x, and management kept full-year capex guidance at about 4% of revenue.
Reported third-quarter revenue growth was 10% year over year on an FX-neutral basis. Mexico saw 12% higher surgery volumes and 34% higher chemotherapy/radiotherapy sessions; Peru saw 21% higher surgery volumes and 18% higher chemotherapy/radiotherapy sessions; Colombia revenue increased 12% in local currency. Management said Mexico adjusted EBITDA grew 5% year over year, while Colombia adjusted EBITDA declined 30% and Peru adjusted EBITDA fell 6%. Year to date, net operating cash flow increased 62% to PEN 713 million and free cash flow surged 95% to PEN 626 million; cash position rose 83% to PEN 614 million, and leverage improved to 3.5x. For full-year 2026, revenue growth is still expected at 10% to 14% FX-neutral, adjusted EBITDA is expected to be broadly stable or slightly down year over year, and capex is guided at about 4% of consolidated revenues.
Jesús Zamora said the company maintained growth momentum across the platform, with Mexico showing improving profitability, Peru still having significant growth potential, and Colombia remaining a strong market despite near-term pressure. His tone was confident but candid: he repeatedly described the quarter as tough and said management is focused on restoring predictability, improving earnings quality, and addressing exogenous issues. He emphasized that Mexico is gaining traction, Peru’s integrated model remains intact, and Colombia should recover after the contract termination and operational changes.
Gisele Ferrero focused on the mechanics behind the quarter: Mexico posted 5% adjusted EBITDA growth, Peru absorbed PEN 18 million of revenue adjustments tied to prior billing matters, and Colombia was hurt by an unprofitable oncology risk-sharing contract plus price caps. She said the contract represented about 4% of Colombia revenue and was terminated, and she quantified that roughly 70% of Colombia’s EBITDA decline versus last year came from that contract, with the remaining 30% from price caps. She also highlighted stronger cash generation, with operating cash flow up 62% to PEN 713 million, free cash flow up 95% to PEN 626 million, cash at PEN 614 million, and a blended interest rate of 10.38% year to date.
Analysts pressed management on whether Colombia’s contract problem could spread to other risk-sharing arrangements; management said it was a one-off and not indicative of contagion across the rest of the portfolio. On Mexico, management said utilization can rise by roughly 2 to 3 percentage points per year and that margin recovery should continue as occupancy and volumes build, with Monterrey cited at 41% occupancy and a 28% EBITDA margin. Other questions covered Peru billing normalization, where management said the effects should work through over the coming quarters and normalize in the second half of 2027, plus the 2029 bond rundown, where management said it is evaluating refinancing options but has more than three years to address the maturity.
The positive case is that core demand is still growing across all three countries, and the company is converting that growth into better cash generation and lower leverage. Management sounded confident that Mexico is turning into a sustained growth and margin recovery story, while Peru’s underlying operating trends remain strong once billing issues clear.
The main risk is that profitability remains vulnerable to country-specific shocks, especially in Colombia where a single contract and price caps caused a major EBITDA hit. Peru is also still dealing with billing reconciliations that management says could affect results for several more quarters, and management expects fourth-quarter pressure to continue from Peru and Colombia even as revenue growth stays intact.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 75.9%
- Shares Outstanding
- 74.06M
- Float Shares
- 56.17M
of shares held by institutions
51 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 1.09M | ▼ 28.60K |
| Morgan Stanley | 573.95K | ▼ 422 |
| Renaissance Technologies LLC | 537.89K | ▼ 28.21K |
| Marshall Wace, Llp | 451.30K | ▼ 33.27K |
| Two Sigma Investments, LP | 387.40K | ▲ 71.71K |
| Verde Servicos Internacionais S.A. | 308.21K | 0 |
| Pekin Hardy Strauss, Inc. | 288.23K | ▼ 6.00K |
| Ubs Group AG | 268.79K | ▲ 67.99K |
| Sagil Capital Llp | 268.78K | ▲ 268.78K |
| Arrowstreet Capital, Limited Partnership | 239.98K | ▲ 173.23K |
| Mount Lucas Management LP | 175.00K | 0 |
| Winton Group Ltd | 129.13K | ▲ 110.08K |
Held by 3 ETFs
Biggest fund positions in AUNA by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 29, 26 | Zamora Leon Jesus | buy | 6,420 |
| May 28, 26 | Zamora Leon Jesus | buy | 9,220 |
| May 26, 26 | Zamora Leon Jesus | buy | 30,000 |
| May 20, 26 | Zamora Leon Jesus | buy | 5,814 |
| May 28, 26 | Wilton John | sell | 17,574 |
| Mar 18, 26 | Zamora Leon Jesus | other | 0 |
| May 27, 26 | Zamora Leon Jesus | buy | 23,273 |
| May 26, 26 | Zamora Leon Jesus | buy | 8,727 |
| Mar 18, 26 | Zamora Leon Jesus | other | 0 |
| Mar 18, 26 | Zamora Leon Jesus | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our AUNA coverage
Recent articles, reports, and earnings notes.
No research on AUNA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AUNA report →Auna S.A. (AUNA) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 18
Auna Q3 Earnings Call Highlights
marketbeat.com · Nov 18
Auna Announces 3Q26 Financial Results
businesswire.com · Nov 17
Auna (NYSE:AUNA) Shares Cross Below 200 Day Moving Average – Time to Sell?
defenseworld.net · Oct 27
Auna Investor Day: Colombia Pressure Prompts 2026 EBITDA Growth Reset
marketbeat.com · Oct 23
Auna S.A. (AUNA) Analyst/Investor Day Transcript
seekingalpha.com · Oct 23
Auna Announces Preliminary Update to Full-Year 2026 Outlook
businesswire.com · Oct 22
Auna Announces Fulfillment of All Conditions Precedent for Construction of Centro Ambulatorio Trecca in Lima
businesswire.com · Oct 21
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.